| (Values in U.S. Thousands) | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 | Jun, 2020 |
| Sales | 81,000 | 107,400 | 96,670 | 65,630 | 27,630 |
| Sales Growth | -24.58% | +11.10% | +47.30% | +137.53% | +277.46% |
| Net Income | -15,840 | -17,050 | -110,170 | -58,290 | -13,620 |
| Net Income Growth | +7.10% | +84.52% | -89.00% | -327.97% | +49.80% |
Aytu Biopharma Inc (AYTU)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.2400 -0.0100 (-0.80%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.2400 unch (unch) 16:00 ET
for Fri, Mar 21st, 2025
Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado.
Fiscal Year End Date: 06/30